
Pharmaceuticals · Listed on BSE · 20 Mar 2026 - 24 Mar 2026
Jagat JoshiOne of the leading companies,” Speciality Medicines” was founded in 2021 and started a business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology, and rare diseases.
Moreover, the company operates in two ways: (a) contract manufacturing of finished formulations for international markets, and (b) marketing and distribution of sourced specialty pharmaceutical products.
Further, the company has around 7 registered products overseas, and 54 products are in the registration process across 5 countries.
| Date & Time | GMP (₹) | Est. Listing Price | Est. Gain (%) | Est. Profit / Lot (₹) |
|---|---|---|---|---|
| 30-Mar-2026 07:00 AM | +₹0 | ₹124 | +0.00% | ₹0 |
| 29-Mar-2026 05:00 PM | +₹0 | ₹124 | +0.00% | ₹0 |
| 28-Mar-2026 05:00 PM | +₹0 | ₹124 | +0.00% | ₹0 |
| 27-Mar-2026 05:00 PM | +₹0 | ₹124 | +0.00% | ₹0 |
| 26-Mar-2026 05:00 PM | +₹0 | ₹124 | +0.00% | ₹0 |
| 25-Mar-2026 05:00 PM | +₹0 | ₹124 | +0.00% | ₹0 |
| 24-Mar-2026 05:00 PM | +₹0 | ₹124 | +0.00% | ₹0 |
| 23-Mar-2026 05:00 PM | +₹0 | ₹124 | +0.00% | ₹0 |
| 21-Mar-2026 05:00 PM | +₹0 | ₹124 | +0.00% | ₹0 |
| 20-Mar-2026 05:00 PM | +₹0 | ₹124 | +0.00% | ₹0 |
| 19-Mar-2026 05:00 PM | +₹0 | ₹124 | +0.00% | ₹0 |
| 18-Mar-2026 05:00 PM | +₹0 | ₹124 | +0.00% | ₹0 |
| 17-Mar-2026 05:00 PM | +₹0 | ₹124 | +0.00% | ₹0 |
| Category | Subscription (x) | Shares Offered | Shares bid for | Total Amount (₹ Cr) |
|---|---|---|---|---|
| QIB (Ex. Anchor) | 96.24x | 21,000 | 20,21,000 | ₹25.06 Cr |
| NII | 1.88x | 10,89,000 | 20,44,000 | ₹25.35 Cr |
| bNII > ₹10L | 2.50x | 7,26,000 | 18,13,000 | ₹22.48 Cr |
| sNII < ₹10L | 0.64x | 3,63,000 | 2,31,000 | ₹2.86 Cr |
| Retail | 0.85x | 10,90,000 | 9,22,000 | ₹11.43 Cr |
| Total | 2.27x | 22,00,000 | 49,87,000 | ₹61.84 Cr |
| Period Ended | 31 OCT 2025 | 31 MAR 2025 | 31 MAR 2024 |
|---|---|---|---|
| Total Income | 36.93 | 58.54 | 27.66 |
| Profit After Tax | 6.06 | 8.61 | 2.93 |
| EBITDA | 6.51 | 9.09 | 5.26 |
| NET Worth | 36.47 | 30.42 | 15.06 |
| Reserves and Surplus | 30.04 | 23.98 | 9.95 |
| Total Borrowing | 4.81 | 5.05 | 2.86 |
| Company Name | EPS (₹) | P/E (x) | NAV (₹) | RoNW (%) | Income (₹ Cr) |
|---|---|---|---|---|---|
| Mono Pharmacare Limited | 1.75 | 13.87 | 17.66 | 9.90 | 168.34 |
| Trident Lifeline Limited | 10.22 | 27.59 | 56.05 | 18.23 | 86.96 |
| Remus Pharmaceuticals Limited | 65.21 | 12.25 | 434.25 | 15.02 | 620.36 |
Parth B Goyani, Goyani Sumit Babubhai are the company's promoters of Speciality Medicines.
| Particular | Pre IPO | Post IPO |
|---|---|---|
| Promoter and Promoter Group | 59.28% | 43.44% |
| Others* | 40.72% | 56.56% |
Join the discussion
Please sign in to leave a comment or reply.